Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply

Armstrong AW, Nong Y, Merola JF. Robustness of Network Meta-Analysis in Chronic Plaque Psoriasis-Reply. JAMA Dermatol. 2026 Sep 23. doi: 10.1001/jamadermatol.2026.3645. Epub ahead of print.[...]

Moderate-to-severe chronic spontaneous urticaria is associated with increased risk of immune-mediated diseases: A population-based study

Smart K, Ure A, Johnsen N, Aflatooni S, Cortes JA, Palma G, Nong Y, Borba AJ, Levins PC, Armstrong AW. Moderate-to-severe chronic spontaneous urticaria is[...]

Ethical issues when teledermatology employs tape-stripping molecular diagnostics

Iurillo AM, Zhou AE, Sloan B, Kerr PE, Grant-Kels JM. Ethical issues when teledermatology employs tape-stripping molecular diagnostics. Clin Dermatol. 2026 Sep 23:S0738-081X(26)00270-1. doi: 10.1016/j.clindermatol.2026.09.023.[...]